Brain aging, Alzheimer's disease, and mitochondria  by Swerdlow, Russell H.
Biochimica et Biophysica Acta 1812 (2011) 1630–1639
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReview
Brain aging, Alzheimer's disease, and mitochondria
Russell H. Swerdlow ⁎
Department of Neurology, University of Kansas School of Medicine, Kansas City, KS, USA
Department of Biochemistry and Molecular Biology, University of Kansas School of Medicine, Kansas City, KS, USA
Department of Molecular and Integrative Physiology, University of Kansas School of Medicine, Kansas City, KS, USAAbbreviations: AACD, age-associated cognitive declin
ory impairment; Aβ, beta amyloid; AD, Alzheimer's di
protein; BACE, beta secretase; COX, cytochrome oxid
cybrid, cytoplasmic hybrid; DMN, default mode netw
chain; FDG, ﬂuorodeoxyglucose; fMRI, functional mag
positron emission tomography; PIB, Pittsburgh compou
pairment; mtDNA, mitochondrial DNA; PCR, polymeras
⁎ Landon Center on Aging, MS 2012, 3901 Rainbow Bl
Tel.: +1 913 588 6970; fax: +1 913 588 0681.
E-mail address: rswerdlow@kumc.edu.
0925-4439/$ – see front matter © 2011 Elsevier B.V. Al
doi:10.1016/j.bbadis.2011.08.012a b s t r a c ta r t i c l e i n f oArticle history:
Received 2 August 2011
Received in revised form 26 August 2011
Accepted 29 August 2011
Available online 2 September 2011
Keywords:
Aging
Amyloid
Brain
Dementia
Alzheimer's disease
MitochondriaThe relationship between brain aging and Alzheimer's disease (AD) is contentious. One view holds AD results
when brain aging surpasses a threshold. The other view postulates AD is not a consequence of brain aging.
This review discusses this conundrum from the perspective of different investigative lines that have tried
to address it, as well as from the perspective of the mitochondrion, an organelle that appears to play a role
in both AD and brain aging. Speciﬁc issues addressed include the question of whether AD and brain aging
should be conceptually lumped or split, the extent to which AD and brain aging potentially share common
molecular mechanisms, whether beta amyloid should be primarily considered a marker of AD or simply
brain aging, and the deﬁnition of AD itself.e; AAMI, age-associated mem-
sease; APP, amyloid precursor
ase; CSF, cerebrospinal ﬂuid;
ork; ETC, electron transport
netic resonance imaging; PET,
nd B; MCI, mild cognitive im-
e chain reaction
vd, Kansas City, KS 66160, USA.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD), the most common neurodegenerative
disease, affects 5.4 million Americans and is believed to cost the econ-
omy $385 billion per year [1,2]. Currently available treatments mini-
mally impact the disease and more effective interventions are
needed. Accomplishing this will require a sophisticated understand-
ing of its cause or causes.
The deﬁnition of AD has varied over the years [3]. Initially, and a
number of decades thereafter, AD was considered a form of presenile
dementia [4,5]. Elderly demented individuals were not generally di-
agnosed with AD, even though their brains frequently contained neu-
ritic plaques and neuroﬁbrillary tangles. Later, the deﬁnition was
changed to include all patients, regardless of age, who were felt to
have a plaque-and-tangle related dementia.
Large numbers of elderly individuals develop a dementia syn-
drome and have enough plaques and tangles to qualify for an AD di-
agnosis [3]. One in every eight persons over 65 is estimated to have
AD, 40–50% past the age of 85 may have it, and in some very elderlysub-groups the ﬁgure appears to surpass 50% [2,6–8]. If AD diagnostic
criteria are relaxed so that individuals with lesser degrees of cognitive
decline and lower brain plaque and tangle burdens are included, the
number of those affected becomes even larger [7,9–11].
For epidemiologic reasons alone AD is therefore a somewhat
unique disease. According to some studies its incidence and preva-
lence continuously increases with advancing age, and appears to
reach a point at which a majority of those beyond a certain age likely
have it [3,8,12]. Because of the profound relationship between ad-
vancing age and AD, it is worth considering the extent to which AD
and brain aging constitute discrete phenomena, and to also consider
the extent to which they overlap. This review will consider this
topic from a clinical perspective, a brain pathology perspective, and
ultimately from the perspective of the mitochondrion, an organelle
implicated in both aging and AD paradigms. In doing so, it will at-
tempt to address the following questions: what is brain aging, and
what is AD?
2. Alzheimer's disease versus brain aging: clinical perspective
Dementia is AD's salient clinical feature. While cognitive decline
represents the dementia syndrome's central characteristic, additional
criteria are speciﬁed and must be satisﬁed [13,14]. Most importantly,
a patient's cognitive decline should be so extensive it degrades inde-
pendence, social abilities, or job performance. This part of the deﬁni-
tion helps distinguish benign, minor degrees of cognitive change from
more serious, major degrees of cognitive change.
Applying a syndromic diagnosis of dementia, though, is often dif-
ﬁcult. For the clinician, the decision over whether a patient has
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Fig. 1. Two different cognitive decline schemes. (A) Cognitive decline that accompanies
brain aging does not cause dementia and is mechanistically distinct from the cognitive
decline that occurs during MCI and AD. This model is inferred from neuropsychology
studies. (B) Cognitive decline is part of a single continuum that, given enough time,
has the ability to progress to dementia in most people. This model suggests cognitive
decline in aging individuals does not necessarily represent a mechanistically or clinical-
ly benign process and implies the presence of a common underlying mechanism. This
view is consistent with the experience of Memory Disorders Clinics that longitudinally
evaluate patients with memory complaints.
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clear-cut. Also, some individuals may decline substantially yet still
be able to compensate, while small declines may signiﬁcantly impair
other individuals. To help address this latter limitation, in addition to
determining how a patient performs relative to age-matched “nor-
mals” on cognitive tests, whether performance occurred at or below
the patient's own “expected” level is also assessed. This approach
can identify cognitive deﬁcits in persons whose exam performance
surpasses that of their peer group.
Another problem arises from the fact that when it comes to cogni-
tive decline, “benign” is an arbitrary term. Cognitive decline only re-
mains benign for as long as it remains compensated. For much of
the latter part of the 20th century it was assumed that although cog-
nitive changes occur during aging, “age-related” decline rarely affects
functional abilities and, from an etiology perspective, is unrelated to
cognitive changes that occur in AD [3].
This view was supported by studies of “healthy” brain aging,
which concluded advancing age adversely affects some cognitive
skills but typically spares others [15–18]. Memory encoding, working
memory (a component of executive function), and processing speed
all decline with age. Although this decline probably proceeds
throughout adulthood it truly becomes evident after the age of 60. Se-
mantic knowledge and autobiographical memory, on the other hand,
tend to remain intact.
Clinical studies of age-related cognitive change have been further
interpretedwithin the context of neuroimaging studies of non-demented
adults [15]. These neuroimaging studies show advancing age and pre-
frontal cortical atrophy positively correlate, while hippocampal volumes
change to a lesser extent. Therefore, cognitive skills that decline with age
localize to the prefrontal lobes, a part of the brain that steadily atrophies
with age in non-demented individuals. Cognitive skills that are relatively
stable in non-demented, aged individuals localize to the hippocampi, a
part of the brain that shows some but relatively limited age-related atro-
phy in non-demented individuals. To many, this suggests an age-related
decline in prefrontal lobe-associated cognitive performance is normal
and expected,while an age-related decline inmedial temporal lobe-asso-
ciated cognitive performance is abnormal and not expected in healthy
individuals.
In the 1980s and 1990s operational criteria designed to deﬁne this
benign, age-related cognitive change phenomenon were developed.
“Age-associated memory impairment” (AAMI) applied to elderly in-
dividuals with cognitive complaints, no dementia, and cognitive test
scores below those of young adults [19]. “Age-associated cognitive
decline” (AACD) could be diagnosed in elderly individuals with cogni-
tive complaints, no dementia, and cognitive test scores more than one
standard deviation below the mean of age-matched, complaint-free
cohorts [20,21].
In practice, this approach to age-related cognitive change now ap-
pears excessively optimistic. Over time, cognitive decline in those
with AAMI and AACD tends to progress, the line from no dementia
to dementia is frequently crossed, and AD is often diagnosed [3,22–
31]. Among Memory Disorders specialists there is an increasing real-
ization that objective and possibly even subjective cognitive decline
in elderly individuals could represent incipient AD. To acknowledge
this concern, a “mild cognitive impairment” (MCI) syndrome was de-
ﬁned and formal criteria developed [32]. These criteria have under-
gone several minor modiﬁcations over the past decade, but in
general MCI is diagnosed in persons with changing cognitive abilities,
objective evidence of cognitive decline, and functional independence
(i.e. no dementia) [32–35].
MCI and AACD criteria overlap. The biggest difference between
these two syndromes is that AACD implies changes are due to brain
aging and of minimal concern, while MCI implies changes are not
due to brain aging and are of substantial concern (Fig. 1). This point
brings us back to the questions posed in the Introduction section:
what is brain aging, and what is AD?3. Alzheimer's disease versus brain aging: pathology perspective
Several phenomena commonly observed in aging brains are consid-
ered consequences of aging. Atrophy and small degrees of whitematter
change, especially in the vicinity of the lateral ventricles, are not felt to
necessarily represent harbingers of disease [36–40]. This does not infer
changes seen in the “healthy” aging brain do not also occur in AD, al-
though patterns may differ. Hippocampal atrophy is more noticeable
in demented subjects with AD than it is in non-demented subjects
[41]. AD subjects show more pervasive white matter change [42–46].
Differences between hippocampi from AD and age-matched, cog-
nitively intact individuals are reported. In brains from cognitively in-
tact subjects, hippocampal CA1 neuron counts do not correlate with
age [47–49]. Brains from AD subjects have fewer CA1 neurons than
control subjects [47]. The CA1 neuron count data have been used to
argue brain aging and AD are discrete events. Deducing mechanistic
inferences from descriptive, observational studies, though, is often
dangerous. A more conservative conclusion is that reduced CA1 neu-
ron counts associate with dementia, and as long as an aging individu-
al is not demented CA1 neuron counts should remain relatively
constant.
From a pathology perspective, neuritic plaques and neuroﬁbrillary
tangles serve as a dividing line between AD and other dementias.
Neuritic plaques are extracellular cortical structures that contain am-
yloid protein. The main plaque amyloid protein constituent is beta
amyloid (Aβ), which itself derives from processing of a larger protein
called the amyloid precursor protein (APP). Neuroﬁbrillary tangles
are intraneuronal cortical structures that consist of tau protein aggre-
gates. Demented individuals who do not have plaques and tangles do
not qualify for a diagnosis of AD.
In demented patients without plaques and tangles, alternative pa-
thology that suggests a non-AD diagnosis is often detected. Frequent-
ly, however, alternative pathologies are also seen in demented
patients with plaques and tangles [50–52]. In these cases, a judgment
must be made as to which pathology is most likely responsible for the
clinical dementia syndrome. The histological dividing line between
AD and other dementias, therefore, is not always clear.
In addition, the simple presence of plaques and tangles do not dis-
tinguish demented from non-demented individuals because brains of
non-demented individuals frequently contain plaques and tangles.
Tangles are commonly observed in aged individuals irrespective of
cognitive status [53–56]. Tau phosphorylation, an event believed to
precede tangle formation, is actually found in the temporal lobe
transentorhinal region of young adults and with advancing age tau
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[57]. Decades of clinical–pathological correlative studies, now corrob-
orated by a decade of neuroimaging studies, also demonstrate a siz-
able percentage of the non-demented elderly have plaques
[40,51,54,55,58–68]. To date, Pittsburgh Compound B positron emis-
sion tomography (PIB PET) constitutes the most extensively used pla-
que imaging approach. PIB binds ﬁbrillar Aβ. Brain retention may
reﬂect plaque or non-plaque ﬁbrillar Aβ binding, and possibly also
Aβ-independent phenomena, but PIB retentionwithin a brain generally
indicates the presence of Aβ plaques [69,70]. Studies of non-demented
elderly cohorts overall report approximately 20–40% are PIB-positive
[67,68,71–78].When analyzed according to age, though, the percentage
of non-demented subjects who are PIB-positive increases with advanc-
ing age and the majority of those past 80 years of age (65%) show PIB
retention [67]. Brain histology surveys suggest that brains from individ-
uals surviving to age 85 and beyond have at least some degree of plaque
and tangle pathology [9,54,79]. Plaque burdens in brains of very elderly,
non-demented APOE2 carriers are reported to reach very high levels
[80].
For those who have plaques but not dementia, what does the pres-
ence of brain Aβ pathology imply? One possibility is that relation-
ships between Aβ and brain aging exist independent of AD. If so,
then Aβ could constitute either a marker of brain aging or else an ac-
tual cause of brain aging. The other possibility is that relationships be-
tween Aβ and brain aging do not exist, and that changes in Aβ always
indicate the presence of AD. Much of the AD research ﬁeld now seems
headed in the latter direction. This is reﬂected by the recent adoption
of AD diagnostic criteria that classify cognitively normal individuals
with brain plaques or low cerebrospinal ﬂuid Aβ levels as having
“preclinical AD” [77].
4. Brain aging and the new Alzheimer's disease diagnostic criteria
According to the new AD diagnostic criteria cognitive decline and
an absence of alternative dementia-associated pathology are no lon-
ger required features. At least for research purposes, to qualify for a
diagnosis of AD altered brain or CSF Aβ is now the sole requirement
[77]. Because most very elderly individuals have Aβ plaques, by ex-
tension most very elderly people have AD. Also, since most young in-
dividuals will develop Aβ deposits if they live long enough [9,54,79],
almost the entire population that doesn't already have AD is on
their way to developing AD [3]. According to the preclinical AD cri-
teria, therefore, it is difﬁcult to see how brain amyloidosis and brain
aging could be considered separate entities arising through indepen-
dent mechanisms.
It is important to note some persons may not develop brain amy-
loid pathology no matter how long they live [81]. Exemplifying this is
a report of a 115 year-old supercentenarian (a term applied to indi-
viduals beyond 110 years of age) who did not clinically dement dur-
ing life and whose brain, on autopsy, showed very limited tau
pathology and almost no ﬁbrillar Aβ deposition [82]. It is difﬁcult,
though, to view this as an example of normal brain aging. Supercen-
tenarians are so exceedingly rare this report may more correctly be
considered an exception to, as opposed to example of, normal brain
aging.
The 2011 AD criteria reﬂect the impression, now held by many AD
clinicians, that cognitive decline in AD begins long before dementia
syndrome criteria are met [3]. Various studies suggest this pre-de-
mentia period of cognitive decline lasts at least a decade and perhaps
even many decades [83–86]. The new AD criteria are therefore
designed to include rather than exclude persons who may be in the
earliest stages or at a high risk of developing AD. This is accomplished
by stipulating everyone with either ﬁbrillar Aβ deposits or low CSF Aβ
has AD, or at least a modiﬁed form of AD [77]. Those who meet MCI
clinical criteria and have Aβ changes qualify for a diagnosis of “MCI
due to AD” [35] or “prodromal AD” [87]. As was discussed earlier,cognitively intact individuals with Aβ changes qualify for a diagnosis
of preclinical AD [77]. Based on studies that show clinical AD [6,8],
MCI [88], and preclinical AD [67] are common in the elderly, by this
scheme that vast majority of those past the age of 85 have AD (Fig. 2).
According to the new criteria, the primary dividing line between
AD and brain aging is the presence or absence of brain or CSF Aβ
changes. Those with Aβ changes have AD, regardless of their clinical
status. Those with cognitive decline but no Aβ changes may be man-
ifesting signs of brain aging, AD that for unclear reasons does not yet
show but will eventually show Aβ changes, or another cause of cogni-
tive decline.
The new AD diagnostic criteria will no doubt affect clinical study
design. In the future, what will constitute a “control” subject? This
question is important to address, as study design inﬂuences results
and by extension interpretation. After all, age-dependent increases
in AD incidence and prevalence suggest many of today's control sub-
jects are, in fact, tomorrow's AD subjects. Looking back, the new cri-
teria further imply that over the past several decades a substantial
percentage of subjects included in control groups were not pure con-
trols. This has implications for a variety of investigations, such as as-
sociation studies. In the future, instead of assuming cohort purity,
we will increasingly need to distinguish cohorts by age of symptom,
sign, or biomarker onset.
In addition to using Aβ phenomena to distinguish AD from “nor-
mal” brain aging, the new criteria make one critical mechanistic as-
sumption. Aβ is identiﬁed as an “upstream” AD biomarker [77].
Other biomarkers, including increased CSF tau, CSF phospho-tau,
and decreased glucose utilization (as demonstrated by ﬂuorodeoxy-
glucose PET; FDG PET), are identiﬁed as “downstream” biomarkers.
This is based on studies that suggest ﬁbrillar Aβ deposition or low
CSF Aβ either can or does precede the other changes [76,89]. Chrono-
logical precedence for Aβ over tau is mostly deduced from studies
that ﬁnd CSF Aβ levels are already low during the earliest stages of
cognitive change and do not drop more over time; CSF tau concentra-
tions are more dynamic over the course of MCI and AD and changes
correlate to some extent with cognitive decline; and tau changes cor-
relate better with acknowledged late-appearing biomarkers such as
hippocampal atrophy [90–94]. Whether Aβ changes precede either
age-related or AD-related brain bioenergetic changes is less clear-
cut, especially since abundant data from human and cell-based stud-
ies either suggest or demonstrate bioenergetic factors regulate both
APP processing and Aβ production [95–100].
In any event, as far as “upstream-downstream” relationships are
concerned biomarker correlation or chronology does not address
whether one biomarker change drives another. Basing mechanistic
inferences on descriptive observation is notoriously unreliable; such
inferences are frequently inaccurate and occasionally misleading. Fi-
nally, using Aβ phenomena to distinguish between AD and brain-
aging does not address what causes these phenomena in the ﬁrst
place. To address the question of whether brain aging and AD consti-
tute discrete or continuous entities will probably require a critical un-
derstanding of underlying mechanisms.5. Mitochondria and the aging brain
Brain aging associates with or results from particular molecular
phenomena. As aging is itself AD's strongest risk factor, it is worth
considering whether such phenomena also play a role in AD. Aging
is an incompletely understood process that different hypotheses at-
tempt to explain. Most predict time-dependent, cumulative change
plays a role, specify a potentially responsible change, and postulate
possible underlying mechanisms. The proposed change variably im-
plicates a toxic accumulation, functional decline, or DNA alteration.
Such changes, however, may not occur in isolation and increasingly
appear to be inter-related [101].
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Fig. 2. New AD criteria imply most of the elderly population has some form of AD. An attempt was made to estimate the percentage of the population over the age of 85 that has at
least some form of AD. The studies of Evans et al. and Corrada et al. suggest probably between 30 and 50% of this group has AD; the study of Lopez et al. suggests up to 30% of this
group has MCI, although that study did not incorporate biomarker endpoints; and the PIB-PET study of Rowe et al. suggests approximately 65% of cognitively intact individuals in
this age group are PIB positive. This breakdown is shown in (A) as a classiﬁcation of 100 individuals, while (B) shows the estimated data in bar graph formwith estimated error bars.
*The ﬁgure assumes not all of those with clinical MCI would qualify for a diagnosis of MCI due to AD, and therefore estimates that with biomarker criteria applied a more conser-
vative 20% would qualify for MCI due to AD.
1633R.H. Swerdlow / Biochimica et Biophysica Acta 1812 (2011) 1630–1639Some aging paradigms feature mitochondria [102–105]. Numer-
ous studies certainly ﬁnd mitochondrial changes occur with advanc-
ing age [106,107]. These changes involve both gain and loss of
function. Electron transport chain function declines, while free radical
production increases. These functional alterations may be initiated by
events outside the mitochondria, or primarily by internal phenome-
na. Several studies report mitochondrial DNA (mtDNA) mutation
can initiate aging, or at least accelerate the progression of age-associ-
ated phenotypes [108,109].
Descriptive studies of mitochondria and brain aging indicate rela-
tionships do exist, although these studies cannot assign causality
[107,110,111]. Such investigations are complicated by the fact that
from a bioenergetics perspective the brain is not a homogeneous
organ. Neurons, which have highly aerobic terminals, and astrocytes,
which dependmore on glycolysis to generate energy, increasingly ap-
pear to constitute a reciprocal bioenergetic network. Neuron neuro-
transmitter release seems to activate astrocyte glycolysis and lactate
production; astrocyte-generated lactate in turn fuels neuron oxida-
tive phosphorylation [112–114]. In some respects this bioenergetic
network is reminiscent of the one formed between type I and type
II muscle ﬁbers.
Within the brain, age-related mitochondrial changes include a de-
cline in complex I (NADH:ubiquinone oxidoreductase) and complex
IV (cytochrome oxidase; COX) activity, with preserved complex II
(succinate dehydrogenase) activity [107]. Complexes I and IV are
partly mtDNA-encoded, while complex II is entirely encoded by nu-
clear genes. This pattern of electron transport chain (ETC) decline
suggests mtDNA changes may mediate the observed complex I and
IV functional changes.
Evidence indicates age-related mtDNA changes do in fact occur
within the human brain. Levels of a 5-kilobase deletion that particu-
larly affects mtDNA COX genes increase with age [115]. Another
study cataloged low abundance heteroplasmic mutations in COX1, a
COX subunit gene located on the mtDNA [110]. Multiple mutations
were detected and the mutation frequency increased with age. For
the most part each individual mutation was present in very low
amounts, but the number of mutations seemed to have a cumulativeimpact as the quantity of COX1 mutations within a given brain corre-
lated inversely with its COX activity.
Mitochondrial mass, or at least parameters related to it, also ap-
pear to change during brain aging. Studies are limited, but overall
suggest that with advancing age mitochondrial mass increases or at-
tempts to increase. One polymerase chain reaction (PCR)-based
study reported brain mtDNA content increases with age [116]. An im-
munochemistry-based study that compared hippocampi from old and
young human subjects also found that compared to young subjects,
elderly subjects had higher neuron mtDNA levels [111].
Oxidative stress markers also increase in the aging brain. This
manifests in the form of protein carbonylation, lipid oxidation, and
mtDNA oxidation [117]. MtDNA oxidation, in turn, renders mtDNA
more susceptible to mutation because oxidized bases are misread
during replication and this leads to nucleotide substitutions [118–
120]. Oxidative stress may partly account for mtDNA's relatively
high mutation rate; mtDNA acquires mutations at approximately 10
times the rate of nuclear DNA [121].
The overall context and meaning of these age-related mitochon-
drial changes is unclear but speculation is possible. According to
some versions of mitochondrial aging theory, for various reasons
mtDNA mutation accumulates over time. These mutations eventually
induce ETC dysfunction, most likely in the form of perturbed complex
I and IV activity. This functional decline may activate a compensatory
upregulation of mitochondrial mass.
6. Mitochondria and Alzheimer's disease
Most investigators agree mitochondria from AD subjects differ
from those of age-matched, non-demented subjects. These differ-
ences are reviewed in detail elsewhere, and only those changes that
are most relevant to the AD versus brain-aging debate are now con-
sidered [122,123].
Relative to control brains, in AD brains several mitochondrial en-
zymes have reduced Vmax activities. Examples include two dehydro-
genase enzymes, pyruvate dehydrogenase and ketoglutarate
dehydrogenase [124]. These are nuclear-encoded enzymes that are
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these changes is unknown, although oxidative stress has been postu-
lated to play a role [125].
COX activity is also reduced in AD brain mitochondria [122,126].
The anatomic distribution of the AD COX defect was initially a subject
of debate. Semi-quantitative histochemical techniques used in some
early studies reported it existed only in certain brain regions, and
mRNA expression analyses found low mtDNA gene expression in AD
brains [122]. Based on these ﬁndings some proposed reduced COX ac-
tivity was a secondary response to neurodegeneration. Toxic inhibi-
tion by Aβ, inability to produce adequate levels of the enzyme, and
physiologic downregulation were all considered potential causes.
Numerous studies, though, indicate the AD COX defect is not lim-
ited to speciﬁc brain regions and is in fact anatomically widespread
[122,123]. In addition to the brain, reduced COX activity is also seen
in AD subject platelets and ﬁbroblasts [127,128]. Spectrophotometric
analysis of the holoenzyme reveals the absence of its high afﬁnity cy-
tochrome c binding site and an altered Km [129]. These data argue the
AD COX defect is not simply a consequence of neurodegeneration or
reduced COX protein.
COX activity is lower in MCI subject platelet mitochondria than it
is in platelet mitochondria from control subjects [130]. Cognitively
normal, middle-aged individuals with ADmothers, who have a higher
risk of developing AD thanmiddle aged individuals with AD fathers or
no AD-affected parents [131], have relatively low platelet COX activi-
ties [132]. Young adult APOE4 carriers, who also have an increased AD
risk, have lower posterior cingulate COX activities than young adult
non-APOE4 carriers [133]. In most of the young adult APOE4 carriers
evaluated by this study COX activity was low even in the absence of
ﬁbrillar Aβ. Findings such as these suggest reduced AD COX activity
develops either very early in the course of AD, or that low COX activ-
ity represents an inherited AD risk factor.
Reduced COX activity in non-degenerating tissues, in conjunction
with its apparent maternal transmission, suggests a genetic etiology.
COX has 13 protein subunits. Ten of these are encoded on nuclear
genes and the other three are mtDNA-encoded. Studies were previ-
ously conducted to investigate a possible mtDNA contribution.
These studies used a cytoplasmic hybrid (cybrid) approach in which
neuronal cell lines were ﬁrst depleted of endogenous mtDNA
(Fig. 3) [123,134]. These mtDNA-depleted cells, called ρ0 cells, were
mixed with platelets isolated from different individual AD and control
subjects. ρ0 cells that incorporated platelet mitochondria were isolat-
ed and expanded to create unique cybrid cell lines. All cybrid cell lines
created from a common ρ0 cell strain had the same nuclear back-
ground and differed only in their mtDNA. COX activity in cybrid
lines containing AD subject mtDNA was lower than it was in cybrid
lines containing control subject mtDNA. Other biochemical and mo-
lecular parameters were altered in AD cybrids, and most likely repre-
sent downstream consequences of their mtDNA-dependent COX
defect. Many of these AD cybrid alterations recapitulate phenomena
observed in AD brains and include increased oxidative stress, apopto-
sis markers, and processing of APP to Aβ [123].
A relationship between APP processing and cell bioenergetics cer-
tainly appears to exist [123]. This was directly demonstrated in cell
culture experiments in which COX inhibition and ATP depletion
both reduced non-amyloidogenic, α secretase-mediated APP proces-
sing [95,96,98]. Preventing the α-secretase APP cleavage preserves
Aβ integrity and makes it possible for the β-secretase (BACE) to pro-
duce Aβ derivatives. Free radicals, a byproduct of ETC electron trans-
fer, further appear to activate BACE [135].
Other evidence of an APP-bioenergetics relationship is indirectly
inferred from in vivo studies. Brain plaque deposition anatomically
corresponds to the functional magnetic resonance imaging (fMRI)-
deﬁned default mode network (DMN), a brain region characterized
by relatively high glycolysis rates [69,99,136]. Soluble Aβ levels also
vary throughout the day, rising during wakefulness and falling duringsleep [100]. Soluble interstitial Aβ levels fall in the setting of trauma-
induced coma, and rising levels signal clinical recovery [137]. These
data imply APP processing is a highly regulated process, and suggests
cell bioenergetics at least partly regulate APP processing.
Similar to what is observed in brains of non-demented individuals,
mitochondrial mass changes occur in the AD brain. Most studies re-
port the number of intact, normal appearing mitochondria declines
[111,138]. AD subject hippocampal neurons, however, contain more
degrading or degraded mitochondria than control subject hippocam-
pal neurons [111]. In general, PCR-ampliﬁable mtDNA declines but
when hippocampal neuron mtDNA is quantiﬁed by a non-PCR meth-
od that can detect mtDNA in degraded mitochondria total hippocam-
pal neuron mtDNA levels may actually increase [111,139]. In at least
some hippocampal neurons COX subunit protein levels also increase
[140]. This increase, though, appears to relate to a neuron's structural
integrity. In one study, COX protein was increased in tangle-free neu-
rons, and reduced in tangle-containing neurons [140].
A case can be made that similar to what is observed in non-de-
mented aged subjects, the brains of AD subjects show perturbed mi-
tochondrial function and a subsequent compensatory response.
Perhaps the main differences are that in AD brains defects are more
profound, compensation is often inadequate, and compensatory re-
sponses are more likely to simply break down.
7. Reconciling brain aging andAlzheimer's disease: themitochondrial
cascade hypothesis
The amyloid cascade hypothesis has enormously impacted the AD
ﬁeld. It was formulated in the early 1990s after an APP mutation was
discovered in an autosomal dominant AD kindred [141,142]. In its
current version, the amyloid cascade hypothesis speculates either in-
creased Aβ production or decreased Aβ disposal increases brain Aβ
[143]. The extra Aβ eventually generates ﬁbrils and deposits as pla-
ques, but before this can happen toxic Aβ oligomers form and cause
neurodysfunction, neurodegeneration, neuroﬁbrillary tangles, and
clinical dementia [144].
Mutations that potentially increase Aβ, or at least its 42 amino
acid species (Aβ42), are found in very rare autosomal dominant AD
kindreds that mostly develop AD before the age of 60 [145]. This
form of AD is mutation-dependent, not age-related. Why Aβ42 accu-
mulates in the brains of demented and non-demented elderly indi-
viduals is not known. The amyloid cascade hypothesis assumes in
the common, late-onset AD variants mutations or polymorphisms in
genes that regulate Aβ production or removal directly control Aβ
levels, oligomer formation, and AD itself. If as stipulated Aβ levels
are the primary cause of late-onset AD then other, more upstream
events cannot determine Aβ levels.
APP processing, though, is a highly regulated event. Bioenergetic
metabolism certainly affects APP processing and Aβ production.
With advancing age, mitochondrial function and dynamics change.
These changes alter bioenergetic metabolism and would predictably
increase Aβ production.
The bioenergetics-centric “sporadic AD mitochondrial cascade hy-
pothesis” reﬂects this relationship (Fig. 4) [123,146–148]. Rather than
assuming brain aging and AD are mechanistically divergent phenom-
ena, the mitochondrial cascade hypothesis assumes brain aging and
AD are mechanistically related. According to the mitochondrial cas-
cade hypothesis, mitochondrial function constitutes the crucial link
between brain aging and AD. It deviates from the amyloid cascade hy-
pothesis by predicting age-related changes in mitochondrial function,
rather than mutations or polymorphisms in APP or Aβ processing
genes, primarily account for age-associated brain Aβ changes. In
other words, toxic cascades in AD are not initiated by Aβ, but by
mitochondria.
The mitochondrial cascade hypothesis does not address whether
Aβ functions as a toxic intermediate in late-onset, non-autosomal
Original
cell mtDNA
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Nuc
AD subject
plt. mtDNA
Con. subject
plt. mtDNA
Nuc
Nuc Nuc
AD subject
plt. mtDNA
No mtDNA
No mtDNA Con. subject
plt. mtDNA
ρ0 cells
AD Cybrid Cell Line
Control Cybrid Cell Line
Fig. 3. The cybrid technique. The cybrid technique can be used to evaluate the functional consequences of different mtDNAmolecules. To perform this type of cybrid study, a cell line
is depleted of its endogenous mtDNA; these mtDNA-depleted cells are called ρ0 cells. ρ0 cells are then mixed with non-nucleated cytoplasts or cells (such as platelets) in the pres-
ence of a detergent, which disrupts membranes. This facilitates incorporation of non-nucleated cell mitochondria, which contain mtDNA, within the cytosol of the nucleated cells.
The transferred mtDNA repopulates the nucleated cell to create a “cytoplasmic hybrid”, or cybrid. Cybrid cell lines containing mtDNA from different sources vary only in the orig-
ination of their mtDNA, since the nuclear DNA is equivalent between the cell lines. Each line that is generated can be expanded for use in biochemical or molecular assays. Func-
tional differences between cell lines are believed to reﬂect and arise through differences in their mtDNA. Nuc = nucleus; Con = control; Plt = platelet; AD = Alzheimer's disease.
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biomarker of AD, but is instead a “downstream” marker of evolving
mitochondrial dysfunction. Accordingly, Aβ deposition within an
aging brain simply indicates critical age-related changes are occur-
ring. Initially, adaptive changes likely engage to help preserve physi-
ologic and clinical integrity. Eventually, a point is reached where
adaptive changes are no longer adequate or attempted. At this point
neurodegeneration and clinical dementia result, and brain aging se-
gues into AD.
If correct, the mitochondrial cascade hypothesis has several incon-
venient implications. The main implication is that early-onset, autoso-
mal dominant and late-onset, non-autosomal dominant AD cases do
not share a common etiology. Models based on early-onset, autosomal
dominant AD may therefore provide limited insight into late-onset,
non-autosomal dominant AD. Also, even if anti-Aβ treatments are ulti-
mately found to meaningfully beneﬁt early-onset, autosomal dominant
AD patients, this approachmay turn out not to beneﬁt or onlyminimal-
ly beneﬁt late-onset, non-autosomal dominant AD patients.
8. Conclusions
The AD ﬁeld sits at a crossroads. According to one paradigm, AD is
caused by the accumulation of Aβ, accumulating Aβ necessarily sig-
niﬁes the presence of AD, and reducing Aβ should effectively treat
AD. The other paradigm alternatively postulates in late-onset, non-
autosomal dominant AD Aβ accumulates because of a more upstream
physiologic process, Aβ accumulation marks this upstream process,
and reducing Aβ will only beneﬁt patients if Aβ itself also induces
neurodysfunction.
A better understanding of the processes that mediate AD and brain
aging should inform the brain aging-AD splitting versus lumpingdebate (Fig. 5). One view, which seems particularly pertinent to
cases of autosomal dominant AD, holds divergent mechanisms drive
brain aging and AD. The other view is that shared mechanisms drive
both brain aging and AD. This latter possibility may apply mostly to
late-onset AD and could perhaps explain noted associations between
advancing age, AD prevalence, and AD incidence [8,12].
An alternative to the amyloid cascade hypothesis [141–143], the
mitochondrial cascade hypothesis [123,146–148], sees brain aging
and AD as part of a continuum. This continuum is inﬂuenced by com-
mon underlying mechanisms. The mitochondrial cascade hypothesis
proposes mitochondrial function declines with age, and this decline
promotes some features of brain aging including Aβ accumulation.
When mitochondrial decline surpasses a threshold compensatory
mechanisms fail and late-onset AD ensues. In contrast to the amyloid
cascade hypothesis, which views Aβ as the primary upstream AD bio-
marker, the mitochondrial cascade hypothesis in general sees Aβ
more as a downstream biomarker of brain aging. If the mitochondrial
cascade hypothesis is correct, treatments designed to improve mito-
chondrial function should beneﬁt late-onset AD patients more than
treatments designed to directly reduce Aβ.
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